Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund reduced its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 8.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 441,989 shares of the company’s stock after selling 40,617 shares during the quarter. New York State Common Retirement Fund owned about 0.74% of Twist Bioscience worth $20,539,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Van ECK Associates Corp boosted its position in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after buying an additional 267 shares during the period. Signaturefd LLC raised its stake in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Twist Bioscience by 2.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock worth $734,000 after acquiring an additional 363 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares in the last quarter. Finally, D.A. Davidson & CO. increased its holdings in shares of Twist Bioscience by 3.5% during the third quarter. D.A. Davidson & CO. now owns 19,618 shares of the company’s stock valued at $886,000 after purchasing an additional 664 shares during the period.

Insider Buying and Selling

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,654 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $74,264.60. Following the completion of the transaction, the chief executive officer now owns 673,064 shares in the company, valued at $30,220,573.60. This trade represents a 0.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam Laponis sold 5,886 shares of the company’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the sale, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,180 shares of company stock valued at $1,821,971 over the last ninety days. 3.01% of the stock is owned by company insiders.

Twist Bioscience Stock Down 8.4 %

NASDAQ TWST opened at $41.31 on Friday. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The stock has a market cap of $2.46 billion, a PE ratio of -12.22 and a beta of 1.87. The firm has a 50-day simple moving average of $48.10 and a 200 day simple moving average of $45.75.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company’s quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.75) EPS. On average, research analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. Robert W. Baird increased their price target on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. TD Cowen reissued a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Wolfe Research started coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.